Introduction
Pancreatic cancer (PC) is a fatal disease with high mortality and poor prognosis. 
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Adoptive cellular immunotherapy has demonstrated efficacy for the treatment of various malignant tumors, especially dendritic cells-cytokine-induced killer (DC-CIK) cells mediate immunotherapy. 5, 6 Compared to immunotherapy using other types of cells, such as lymphokine-activated killer (LAK) cells, 7, 8 natural killer (NK) cells, 9, 10 and other immune cells, 11, 12 DC-CIK-mediated immunotherapy exhibited a stronger antitumor ability and broader antitumor spectrum. 13, 14 Cytokine-induced killer (CIK) cell is a heterogeneous subset of T lymphocytes, which primarily consist of CD3 + CD56 + cells and is easy to be collected from human peripheral and umbilical cord blood, and subsequently induced by IFN-γ, anti-CD3 monoclonal antibodies (OKT-3), and IL-2 in vitro. 6 DC are the most potent antigen-presenting cells. DC have the capacity to enhance CIK's cytotoxicity by coculture with CIK cells, which is indicated by increased proportion of CD3 + CD56 + cells and improved levels of cytokines such as IFN-γ and IL-2.
5,15
Clinical application of DC-CIK immunotherapy for PC has been reported in several clinical trials. [16] [17] [18] [19] In a metaanalysis comparing cellular immunotherapy combined with chemotherapy and chemotherapy alone, the former showed significantly prolonged OS, 3 while the discussed outcomes were not complete. Analysis considering overall response rate (ORR) and disease control rate (DCR), patients' quality of life (QoL) and safety were not involved in this analysis. Moreover, the immunotherapy regimens among studies were different (including DC, NK, and LAK), which may influence the analysis of clinical therapy. Our study focused on PC patients treated by DC-CIK immunotherapy and chemotherapy combined therapy or chemotherapy alone, and we performed an up-to-date meta-analysis to provide reliable evidence on the efficacy and safety of DC-CIK immunotherapy in treating PC patients.
Methods search strategy and selection criteria
Data were collected from Web of Science, EMBASE, PubMed, Cochrane Library, Wanfang, and CNKI databases using the key terms of "dendritic cells", "cytokine-induced killer cells" combined with "pancreatic cancer". No language limits were applied. Literature published before May 2017 was involved in our analysis.
The main selection criteria are that PC patients in the experimental group underwent DC-CIK immunotherapy combined with chemotherapy and patients in the control group were treated by chemotherapy alone.
Data collection and quality assessment
Literature screening and data extraction were carried out by two independent reviewers (YZ and XZ), and disagreements were eliminated upon discussing with a third researcher (AZ). Extracted information included first author's names, years of publication, study locations, tumor stages, number of cases, patient ages, therapeutic regimens, administration route, in vitro cell culture conditions, and dosages of utilized immune cells. The quality of the included trials was evaluated based on Cochrane Handbook. 20 
Treatment efficacy
Treatment efficacy was assessed in terms of the complete response (CR) rates, partial response (PR) rates, stable disease (SD) rates, progressive disease (PD) rates, ORR, (ORR = CR + PR) and DCR (DCR = CR + PR + SD). Prognosis was estimated by OS, which was defined as the length of time from the start of treatment to the death of patient from any cause, 21 
statistical analysis
This meta-analysis was performed using RevMan 5.2 (version 5.2, Nordic Cochran Centre, Copenhagen, Denmark). P,0.05 indicates the statistical significance of the difference. Heterogeneity among studies was assessed to determine suitable analysis model. 5, 22 Cochran's Q test was performed to evaluate the homogeneity, and funnel plots were used to assess the publication bias of included studies. I 2 ,50% or P.0.1 indicated that the studies were homogenous. Odds ratio (OR) was the principal measurement for treatment efficacy and is presented with a 95% confidence interval (CI). Sensitivity analysis was conducted to evaluate the consistency of the results and evaluate the influence of single studies on overall risk estimate.
23
Results
search results
A total of 2,127 articles were identified upon initial retrieve; 2,082 articles were excluded because they lacked clinical trial (n=1,876), were unrelated studies (n=64), and were duplicated (n=142). After a detailed assessment of full texts, 14 reviews or meta-analyses, 10 articles without control Table 2 .
Quality assessment
Bias risk assessment is shown in Figure 2 . Seven studies were determined as low risk, four researches were not truly randomized controlled trials, and the remaining three studies lacked clear description of randomization process. Risks of allocation, performance, and detection were low. Two studies absent of follow-up, seven trials with selective 
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Efficacy assessments
In our pooled analysis, patients treated by combined therapy showed higher PR ( Figure Fixed-effect models were used in this analysis because of low heterogeneity (Table 3) .
Prognosis evaluation
In the 14 studies, patients treated by combined therapy had higher OS than those treated by chemotherapy alone ( Figure 4 , immune function evaluation
The immune status of patients was examined before and after treatment. As shown in Figure 6 , after DC-CIK treatment, percentages of CD3 + , CD4 + , and CD3 + CD56 
adverse events' assessment
In the involved clinical trials, no serious adverse events or death occurrence was reported in patients receiving DC-CIK immunotherapy. As shown in Figures S2 and 3 and Table 4 , no significant difference was found on adverse OncoTargets and sensitivity analysis PC patients were treated by DC-CIK immunotherapy in eight trials 24, 25, 27, 28, 31, [33] [34] [35] and by CIK alone in the other six trials. 16, 17, 26, 29, 30, 32 Studies were grouped according to different immunotherapy strategies (CIK or DC-CIK), and pooled results were compared ( Table 5 ). The comparison showed both CIK and DC-CIK were effective in treating PC, and no obvious difference between these two methods was observed in most pooled analyses including ORR ( Figure S4A ), DCR ( Figure S4B ), and 1-year OS ( Figure S5 ).
Publication bias
Funnel plots drawn for the studies on primary outcomes (1-and 3-year OS, ORR, and DCR) were symmetrical approximately, which indicated generally controlled publication bias and reliability of our primary conclusions ( Figure 8A 
Discussion
In recent years, immunotherapy using DC-CIK was found effective in PC treatment. [16] [17] [18] Even though there was statistical analysis of published clinical trials, the exact therapeutic effects were not systematically evaluated and demonstrated because of sample sizes' variability among these trials. In addition, the different applied protocols in different clinical trials may lead to different clinical response. In this research, we performed an extensive online search followed by rigorous contrasting and combining data analysis in categorization, by which to provide clear and systematical conclusion. Our analysis showed that DC-CIK immunotherapy enhanced the curative effect of chemotherapy for PC, which was supported by markedly increased ORR (P=0.0003) and DCR (P,0.00001) in PC patients treated by combined therapy. With the addition of DC-CIK immunotherapy, prognosis of PC patients was also improved, according to the significantly prolonged survival time (1-year OS, P,0.00001; 3-year OS, P,0.00001) and QoL (P=0.0009).
Previous study has reported the immunosuppressed status in cancer patient, and several researchers found that adjuvant immunotherapy of DC-CIK was able to enhance the efficacy of chemotherapy for various malignant tumors by reconstructing cancer patient's immune function. 5, 6 Our analysis showed that DC-CIK treatment can significantly improve the percentages of CD3 
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low regulatory T-cell subset proportion decreased after DC-CIK immunotherapy. These results indicated that immune function of chemotherapy-treated PC patients was improved after DC-CIK immunotherapy. However, no significant difference was found in CD8 + T cells' proportion and CD4 + /CD8 + ratio between with and without immunotherapy, which may be caused by various choices of treatment opportunity and DC-CIK transfusion dosages in different clinical trials. 6 The balance between Th1 and Th2 cells is crucial in immunotherapy. 5 Our analysis showed that after DC-CIK immunotherapy, IFN-γ (Th1 
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cytokine) level in PC patients was significantly increased, whereas IL-4 (Th2 cytokine) level was obviously decreased, indicating a passably more important role of IFN-γ and IL-4 during the DC-CIK immunotherapy. Safety is a crucial criterion for the popularization of clinical application of DC-CIK immunotherapy. Based on published literature up to May 2017, our meta-analysis shows that DC-CIK immunotherapy is a safe therapeutic strategy for PC, as no significant difference in adverse events was observed between with and without immunotherapy. Most side effects of DC-CIK immunotherapy were well tolerated by PC patients, and no serious adverse events or death occurred during DC-CIK therapy.
In this analysis, PC patients were treated by DC-CIK immunotherapy in eight trials and CIK alone in the other six trials. To provide evidence for making the choice of using CIK or DC-CIK, difference between their therapeutic effects was evaluated by sensitivity analysis, which showed that both CIK and DC-CIK were effective in treating PC without statistical difference. These results are inconsistent with in vitro study in which DC-CIK represented higher antitumor activity than CIK alone and need to be further explored. Moreover, we conducted publication bias to verify the reliability of our result and no obvious bias exists in our primary conclusions.
limitations
A total of 14 included trials, which met our selection criteria, turned out to be conducted on Chinese population. One trial conducted in Korea was included in our research originally but was then excluded because it lacked insufficient data. Besides, data analyzed in this research were collected from published papers rather than original patient records, which may lead to overestimation of curative effects.
Conclusion
Our meta-analysis shows that the combination of DC-CIK immunotherapy and chemotherapy is a promising immune treatment for PC patients. It markedly prolongs PC patients' survival time passably by reconstructing patients' immune function.
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Study or subgroup
Total events
Total (95% CI)
Li (2016) 26 Wang et al (2013) 16 Total events
Subtotal (95% CI)
0.01
Favor (control) Favor (experimental) 26 Wang et al (2013) 16 Li (2016) 26 Wang et al (2013) 16 Total events
Subtotal (95% CI)
Total events
Total (95% CI)
Subtotal (95% CI)
0.01 
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